EC OKs CSL and Arcturus KOSTAIVE, 1st Self-amplifying mRNA COVID-19 Vaccine

 - KOSTAIVE represents a significant advancement in vaccine technology, demonstrating superior immunogenicity and antibody persistence for up to 12 months post-vaccination compared to conventional mRNA COVID-19 vaccines in clinical trials

Global biotechnology leader CSL (ASX: CSL; USOTC: CSLLY) and sa-mRNA pioneer Arcturus Therapeutics (Nasdaq: ARCT) today announced that the European Commission has granted marketing authorization for KOSTAIVE ® (ARCT-154), a self-amplifying mRNA COVID-19 vaccine, for individuals 18 years and older. KOSTAIVE is the first sa-mRNA COVID-19 vaccine to receive approval from the European Commission (EC). KOSTAIVE is currently marketed in Japan against COVID-19.

https://www.prnewswire.com/news-releases/european-commission-approves-csl-and-arcturus-therapeutics-kostaive-the-first-self-amplifying-mrna-covid-19-vaccine-302377086.html